Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Lipid-Lowering Therapy Promotes Post-Op Survival
The Journal of the American Medical Association published the results of a recent study indicating that when statins are given to non-cardiac patients after major surgery, mortality rates drop substantially. In the article, “Lipid-Lowering Therapy and In-Hospital Mortality Following Major Non-Cardiac Surgery,” Vol. 291 No. 17, May 5, 2004, researchers described their observations of the surgical outcomes for more than 780,000 patients who were operated on in 2000 and 2001. They found that administering statins, which stabilize atherosclerotic plaques, within 2 days of surgery decreased death rates in the group that received them by 38% over those in the group of patients who did not receive them.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.